# The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease

> **NCT00002001** · NA · COMPLETED · sponsor: **Glaxo Wellcome**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Zidovudine
- **DRUG:** Zalcitabine
- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00002001
- **Lead sponsor:** Glaxo Wellcome
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002001, "The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00002001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*